CEL-SCI Corporation
AMEX: CVM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Geert R. Kersten
- Employees
- 43
- Headquarters
- Vienna, United States
- IPO year
- 1983
- Market cap
- $7.1M
- Website
- https://cel-sci.com
Loading CVM…
Loading profile data…Frequently asked questions about CVM
What does CEL-SCI Corporation (CVM) do?
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclini...
Where does CVM trade?
CEL-SCI Corporation (CVM) trades on the New York Stock Exchange American.
What sector is CVM in?
CEL-SCI Corporation (CVM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CEL-SCI Corporation?
Geert R. Kersten is the chief executive officer of CEL-SCI Corporation (CVM).
Where is CEL-SCI Corporation headquartered?
CEL-SCI Corporation is headquartered in United States.
Does CVM pay a dividend?
CEL-SCI Corporation (CVM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CVM go public?
CEL-SCI Corporation (CVM) completed its initial public offering in 1983.